WANG Yu, FAN Yu-ping, HU Ye, HUANG Wen-qiang, TENG Xiao-ming. Therapy on male delayed puberty caused by hypogonadotropic hypogonadism by combination of growth hormone and gonadotropin[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(5): 357-358,395. doi: 10.3969/j.issn.1006-0111.2013.05.010
Citation:
|
WANG Yu, FAN Yu-ping, HU Ye, HUANG Wen-qiang, TENG Xiao-ming. Therapy on male delayed puberty caused by hypogonadotropic hypogonadism by combination of growth hormone and gonadotropin[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(5): 357-358,395. doi: 10.3969/j.issn.1006-0111.2013.05.010
|
Therapy on male delayed puberty caused by hypogonadotropic hypogonadism by combination of growth hormone and gonadotropin
-
Reproductive Medicine Center, Shanghai First Maternity and Infant Hospital, Tong-ji University School of Medicine, Shanghai 200040, China
- Received Date: 2013-05-03
- Rev Recd Date:
2013-07-31
-
Abstract
Objective To evaluate the value and safety of combined therapy of growth hormone and gonadotropin on male delayed puberty caused by hypogonadotropic hypogonadism. Methods A retrospective analysis was undergoing in Shanghai First Maternity and Infant Hospital from 2010 Jun to 2012 May. 28 cases with male delayed puberty caused by hypogonadotropic hypogonadism were enrolled. The average age was (15.25±1.11) years. All the cases were given a combined therapy of human chorionic gonadotrophin, follicle stimulating hormone and growth hormone. After 3 months therapy, the growth condition such as sexual hormone levels, height, and volume of testis were recorded to inspect the treatment effect. Results All 28 cases had a follow-up visit. No short term complications occurred. The height and testosterone level was higher than which before therapy (P<0.05). And the volume of testis, follicle stimulating hormone and luteinizing hormone level were significantly higher than before the therapy. Conclusion Combined therapy of human chorionic gonadotrophin, follicle stimulating hormone and growth hormone could be a safe and effective method to treat male delayed puberty caused by hypogonadotropic hypogonadism.
-
References
[1]
|
Silveira LF, MacColl GS, Bouloux PM. Hypogonadotropic hypogonadism[J]. Semin Reprod Med,2002, 20(4):327. |
[2]
|
杨念钦, 王国民. HCG-FSH联合治疗低促性腺激素性性腺功能减退症29例报告[J]. 中国男科学, 2009, 23(12):39. |
[3]
|
狄福松, 崔毓桂, 贾 悦. 促性腺激素治疗男性低促性腺激素性性腺功能减退症的疗效评估[J]. 中华内科杂志,2005, 44(11):836. |
[4]
|
Wang GM, O`Shaughnessy PJ, Chubb C, et al. Effects of insulin like growth factor-I on steroidogenic enzyme expression levels in mouse Leydig cells[J]. Endocrinology,2003, 144(11): 5058. |
[5]
|
Warne DW, Decosterd G, Okada H, et al. A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle-stimulating hormone and human chorionic gonadotropin[J]. Fertil Steril, 2009, 92:594. |
[6]
|
Kanzaki M, Morris PL. Growth hormone regulates steroidogenic acute regulatory protein expression and steroidogenesis in Leydig cell progenitors[J]. Endocrinology,1999, 140(4):1681. |
[7]
|
Zheng JX, Liu ZZ, Yang N. Deficiency of growth hormone receptor does not affect male reproduction in dwarf chickens[J]. Poult Sci,2007, 86(1):112. |
-
-
Proportional views
-